Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01576549 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2127399 in Rheumatoid Arthritis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01576549 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 2 participants.
The verdict
NCT01576549, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will investigate how LY2127399 works in participants with rheumatoid arthritis (RA) who are not adequately responding to methotrexate. Participants will receive LY2127399 via an injection(s) under the skin at 4 week intervals for up to 52 weeks. Key study procedures include biopsies of the lining of an inflamed joint and blood tests to measure RA activity.
Interventions
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01576549
The ClinicalTrials.gov registry entry for NCT01576549 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2127399 is the first listed.
NCT01576549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01576549 about?
NCT01576549 is a clinical study titled "A Study of LY2127399 in Rheumatoid Arthritis". This study will investigate how LY2127399 works in participants with rheumatoid arthritis (RA) who are not adequately responding to methotrexate. Participants will receive LY2127399 via an injection(s) under the skin at 4 week intervals for up to 52 weeks. Key study procedures include biopsies of th...
What is the current status of trial NCT01576549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-05. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01576549?
The interventions under investigation include: LY2127399 (DRUG).
Who is sponsoring clinical trial NCT01576549?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.